8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Nov 12, 2025·SEC
PMV Pharmaceuticals, Inc.(PMVP)Earnings, Financials & Key Ratios
PMVP•NASDAQ
Price updated Jun 19, 2026
AboutPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.Show more
- Revenue$0
- EBITDA-$86M-2.1%
- Net Income-$78M-32.4%
- EPS (Diluted)-1.48-30.0%
- ROE-55.37%-89.5%
PMVP Key Insights
PMV Pharmaceuticals, Inc. (PMVP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Profits declining 17.7% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PMVP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMVP Price & Volume
PMV Pharmaceuticals, Inc. (PMVP) stock price & volume — 10-year historical chart
Loading chart...
PMVP Growth Metrics
PMV Pharmaceuticals, Inc. (PMVP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-313.89%
Return on Capital
10 Years-32.23%
5 Years-35.66%
3 Years-44.84%
Last Year-61.12%
PMVP Recent Earnings
PMV Pharmaceuticals, Inc. (PMVP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.34+17.1%
$0.41
Rev
—
—
Q2 2026
Mar 6, 2026Metric
Actual
Est
EPS
$0.34+15.0%
$0.40
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.40+0.0%
$0.40
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.41-5.1%
$0.39
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.34vs $0.41+17.1% | — |
| Q2 2026 | Mar 6, 2026 | $0.34vs $0.40+15.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.40vs $0.40+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.39-5.1% | — |
Based on last 12 quarters of dataView full earnings history →
PMVP Peer Comparison
PMV Pharmaceuticals, Inc. (PMVP) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RAIN | 16.75M | 2.06 | -1.72 | -901.82% | ||||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 APLS | 5.25B | 41.03 | 227.94 | 28.46% | 12.95% | 39.71% | 1.31 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 |
Compare PMVP vs Peers
PMV Pharmaceuticals, Inc. (PMVP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PMVP Income Statement
PMV Pharmaceuticals, Inc. (PMVP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 338K | 388K | 318K | 1.28M | 650K | 1.26M | 1.14M | 0 | 66K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -338K▲ 0% | -388K▼ 14.8% | -318K▲ 18.0% | -1.28M▼ 302.8% | -650K▲ 49.3% | -1.26M▼ 93.4% | -1.14M▲ 9.0% | 0▲ 100.0% | -66K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -14.79% | 18.04% | -302.83% | 49.26% | -93.38% | 8.99% | 100% | - |
Operating Expenses | 18.89M | 26.25M | 34.62M | 57.01M | 76.39M | 78.88M | 84.3M | 86.21M | 83.6M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.04M | 5.49M | 11.01M | 20.83M | 24.72M | 24.25M | 26.92M | 16.33M | 15.89M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 13.85M | 20.76M | 23.61M | 36.19M | 51.67M | 54.63M | 57.38M | 69.88M | 67.7M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -18.89M▲ 0% | -26.64M▼ 41.0% | -34.94M▼ 31.2% | -58.29M▼ 66.8% | -77.04M▼ 32.2% | -80.13M▼ 4.0% | -85.45M▼ 6.6% | -86.21M▼ 0.9% | -83.66M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -41% | -31.18% | -66.83% | -32.16% | -4.01% | -6.63% | -0.89% | - |
EBITDA | -18.55M | -26.25M | -34.62M | -57.01M | -76.39M | -78.88M | -84.3M | -86.07M | -83.53M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -41.47% | -31.91% | -64.66% | -33.99% | -3.25% | -6.88% | -2.1% | 5.05% |
D&A (Non-Cash Add-back) | 338K | 388K | 318K | 1.28M | 650K | 1.26M | 1.14M | 133K | 130K |
EBIT | -18.89M | -25.34M | -34.43M | -57.82M | -73.33M | -68.96M | -74.81M | -86.21M | -81.99M |
Net Interest Income | 0 | 1.3M | 651K | 449K | 3.63M | 11.17M | 10.65M | 6.34M | 5.38M |
Interest Income | 1.34M | 1.3M | 651K | 449K | 3.63M | 11.17M | 10.65M | 6.34M | 5.38M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.36M | 1.29M | 508K | 470K | 3.71M | 11.17M | 10.64M | 6.29M | 5.34M |
Pretax Income | -17.54M▲ 0% | -25.34M▼ 44.5% | -34.43M▼ 35.9% | -57.82M▼ 67.9% | -73.33M▼ 26.8% | -68.96M▲ 6.0% | -74.81M▼ 8.5% | -79.91M▼ 6.8% | -78.32M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 3K | 8K | 6K | 23K | -9K | 2K | -16.1M | -2.17M | 25K |
Effective Tax Rate % | -0.02% | -0.03% | -0.02% | -0.04% | 0.01% | -0% | 21.52% | 2.72% | -0.03% |
Net Income | -17.54M▲ 0% | -25.35M▼ 44.6% | -34.44M▼ 35.8% | -57.85M▼ 68.0% | -73.32M▼ 26.7% | -68.96M▲ 5.9% | -58.71M▲ 14.9% | -77.74M▼ 32.4% | -78.34M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -44.55% | -35.85% | -67.96% | -26.75% | 5.94% | 14.87% | -32.42% | -28.7% |
Net Income (Continuing) | -17.54M | -25.35M | -34.44M | -57.85M | -73.32M | -68.96M | -58.71M | -77.74M | -78.34M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.80▲ 0% | -0.59▲ 89.8% | -2.40▼ 306.8% | -1.28▲ 46.7% | -1.61▼ 25.8% | -1.44▲ 10.6% | -1.14▲ 21.0% | -1.48▼ 30.0% | -1.47▲ 0% |
EPS Growth % | - | 89.83% | -306.78% | 46.67% | -25.78% | 10.56% | 20.96% | -30.03% | -313.89% |
EPS (Basic) | -5.80 | -0.59 | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 | - |
Diluted Shares Outstanding | 3.02M | 43M | 44.78M | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M | 53.33M |
Basic Shares Outstanding | 3.02M | 43M | 44.78M | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M | 53.33M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PMVP Balance Sheet
PMV Pharmaceuticals, Inc. (PMVP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 62.24M | 102.09M | 364.76M | 301.29M | 247.01M | 207.41M | 175.66M | 115.23M | 95.78M |
Cash & Short-Term Investments | 61.91M | 101.49M | 361.42M | 297.16M | 241.05M | 203.06M | 169.45M | 112.94M | 93.55M |
Cash Only | 30.31M | 73.28M | 361.42M | 172.47M | 108.3M | 37.71M | 40.88M | 37.98M | 39.13M |
Short-Term Investments | 31.6M | 28.21M | 0 | 124.7M | 132.76M | 165.35M | 128.58M | 74.96M | 54.42M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 3.34M | 822K | 5.95M | 4.35M | 6.2M | 2.28M | 2.23M |
Total Non-Current Assets | 1.22M | 940K | 770K | 30.28M | 23.3M | 44.74M | 15.63M | 1.33M | 782K |
Property, Plant & Equipment | 1.02M | 739K | 569K | 13.15M | 20.49M | 19.05M | 1.55M | 1.04M | 486K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 16.91M | 2.5M | 25.5M | 13.84M | 0 | 6.03M |
Other Non-Current Assets | 201K | 201K | 201K | 221K | 313K | 190K | 235K | 297K | 296K |
Total Assets | 63.46M▲ 0% | 103.03M▲ 62.4% | 365.53M▲ 254.8% | 331.57M▼ 9.3% | 270.31M▼ 18.5% | 252.15M▼ 6.7% | 191.29M▼ 24.1% | 116.56M▼ 39.1% | 96.56M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 62.36% | 254.77% | -9.29% | -18.48% | -6.72% | -24.14% | -39.06% | -158.23% |
Total Current Liabilities | 2.33M | 4.52M | 6.41M | 12.22M | 10.83M | 14.03M | 14.37M | 11.41M | 8.6M |
Accounts Payable | 1.04M | 2.84M | 1.61M | 3.19M | 3M | 3.24M | 6.58M | 3.15M | 1.63M |
Days Payables Outstanding | 1.12K | 2.67K | 1.84K | 908.65 | 1.68K | 939.94 | 2.1K | - | 14.91K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 352K | 403K | 293K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 3.8M | 0 | 4.5M | 5M | 7.86M | 6.67M |
Current Ratio | 26.75x | 22.57x | 56.90x | 24.66x | 22.80x | 14.78x | 12.22x | 10.09x | 11.14x |
Quick Ratio | 26.75x | 22.57x | 56.90x | 24.66x | 22.80x | 14.78x | 12.22x | 10.09x | 11.14x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 107.27M | 168.98M | 0 | 10.79M | 13.45M | 12.43M | 838K | 435K | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 435K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 10.79M | 13.45M | 12.43M | 838K | 0 | 1.62M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 107.27M | 168.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 109.6M | 173.51M | 6.41M | 23.01M | 24.28M | 26.46M | 15.21M | 11.85M | 8.6M |
Total Debt | 107.23M | 0 | 0 | 11.19M | 13.98M | 13.29M | 1.19M | 838K | 293K |
Net Debt | 76.92M | -73.28M | -361.42M | -161.27M | -94.32M | -24.42M | -39.69M | -37.15M | -38.84M |
Debt / Equity | - | - | - | 0.04x | 0.06x | 0.06x | 0.01x | 0.01x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.46x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -46.14M▲ 0% | -70.47M▼ 52.7% | 359.12M▲ 609.6% | 308.56M▼ 14.1% | 246.03M▼ 20.3% | 225.69M▼ 8.3% | 176.08M▼ 22.0% | 104.71M▼ 40.5% | 87.97M▲ 0% |
Equity Growth % | - | -52.74% | 609.58% | -14.08% | -20.27% | -8.27% | -21.98% | -40.53% | -158.84% |
Book Value per Share | -15.26 | -1.64 | 8.02 | 6.84 | 5.40 | 4.70 | 3.41 | 1.99 | 1.65 |
Total Shareholders' Equity | -46.14M | -70.47M | 359.12M | 308.56M | 246.03M | 225.69M | 176.08M | 104.71M | 87.97M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -50.09M | -75.44M | -109.88M | -167.73M | -241.04M | -310M | -368.71M | -446.45M | -464.49M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -13K | -3K | 0 | -78K | -445K | 224K | 139K | 84K | -15K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PMVP Cash Flow Statement
PMV Pharmaceuticals, Inc. (PMVP) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -15.18M | -22.07M | -32.74M | -46.57M | -63.76M | -55.66M | -51.28M | -73.58M | -74.99M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -45.37% | -48.38% | -42.25% | -36.91% | 12.71% | 7.86% | -43.48% | -1073.91% |
Net Income | -17.54M | -25.35M | -34.44M | -57.85M | -73.32M | -68.96M | -58.71M | -77.74M | -78.34M |
Depreciation & Amortization | 338K | 388K | 318K | 1.28M | 650K | 1.26M | 1.14M | 133K | 131K |
Stock-Based Compensation | 1.08M | 908K | 1.93M | 0 | 0 | 12.38M | 8.87M | 5.92M | 3.06M |
Deferred Taxes | 319K | 0 | 152K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -13K | 70K | 143K | 5.87M | 9.47M | -5.76M | -997K | -2.81M | 371K |
Working Capital Changes | 637K | 1.92M | -845K | 4.12M | -568K | 5.43M | -1.59M | 914K | -208K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 267K | 1.8M | -1.23M | 191K | -389K | 235K | 3.34M | -3.42M | -1.96M |
Cash from Investing | 21.69M | 3.23M | 27.91M | -143.58M | -1.37M | -50.55M | 53.35M | 70.17M | 62.28M |
Capital Expenditures | -452K | -109K | -148K | -1.35M | -7.98M | -962K | -655K | -29K | -25K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 148K | 0 | 0 | 0 | 251K | 31K | 31K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 22.14M | 0 | -148K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 61.8M | 292.97M | 2.02M | 958K | 35.58M | 313K | 505K | 495K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 61.7M | 292.97M | 2.02M | 958K | 35.12M | 313K | 505K | 495K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 100K | 6K | 0 | 0 | 456K | 0 | 0 | 0 |
Net Change in Cash | 6.51M▲ 0% | 42.97M▲ 559.6% | 288.14M▲ 570.6% | -188.13M▼ 165.3% | -64.17M▲ 65.9% | -70.59M▼ 10.0% | 2.35M▲ 103.3% | -2.89M▼ 223.2% | -12.21M▲ 0% |
Free Cash Flow | -15.63M▲ 0% | -22.17M▼ 41.9% | -32.89M▼ 48.3% | -47.92M▼ 45.7% | -71.74M▼ 49.7% | -56.62M▲ 21.1% | -51.94M▲ 8.3% | -73.61M▼ 41.7% | -75.02M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -41.87% | -48.31% | -45.71% | -49.72% | 21.08% | 8.27% | -41.72% | -40.4% |
FCF per Share | -5.17 | -0.52 | -0.73 | -1.06 | -1.57 | -1.18 | -1.01 | -1.40 | -1.41 |
FCF Conversion (FCF/Net Income) | 0.87x | 0.87x | 0.95x | 0.81x | 0.87x | 0.81x | 0.87x | 0.95x | 0.96x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 8K | 6K | 0 | 0 | 0 | 0 | 0 | 0 |
PMVP Key Ratios
PMV Pharmaceuticals, Inc. (PMVP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -23.86% | -17.33% | -26.44% | -29.24% | -29.23% | -55.37% | -68.98% |
Return on Invested Capital (ROIC) | - | - | -60.31% | -38.65% | -34.05% | -37.96% | -63.4% | -83.72% |
Debt / Equity | - | - | 0.04x | 0.06x | 0.06x | 0.01x | 0.01x | 0.00x |
FCF Conversion | 0.87x | 0.95x | 0.81x | 0.87x | 0.81x | 0.87x | 0.95x | 0.96x |
Related:PMVP Dividend History·PMVP Revenue History·PMVP Price History·PMVP P/E History·PMVP Financial Ratios·PMVP Institutional Holders
PMVP SEC Filings & Documents
PMV Pharmaceuticals, Inc. (PMVP) SEC filings — annual & quarterly reports (10-K, 10-Q)
PMVP Frequently Asked Questions
PMV Pharmaceuticals, Inc. (PMVP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PMV Pharmaceuticals, Inc. (PMVP) grew revenue by 0.0% over the past year. Growth has been modest.
PMV Pharmaceuticals, Inc. (PMVP) reported a net loss of $78.3M for fiscal year 2025.
Dividend & Returns
PMV Pharmaceuticals, Inc. (PMVP) has a return on equity (ROE) of -55.4%. Negative ROE indicates the company is unprofitable.
PMV Pharmaceuticals, Inc. (PMVP) had negative free cash flow of $75.0M in fiscal year 2025, likely due to heavy capital investments.